Concomitant chemo-radiotherapy in clinical trials: To promote step by step rational development

Critical Reviews in Oncology/Hematology

Volumn 70, Issue 3, 2009, Pages 206-215

  Magné, Nicolas ^a   Chargari, Cyrus ^a   Soria, Jean Charles ^a   Deutsch, Eric ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemo radiotherapy; Clinical trials; Preclinical data; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; PACLITAXEL; TEMOZOLOMIDE; TIRAPAZAMINE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BLEEDING; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG DOSE ESCALATION; GASTROINTESTINAL TUMOR; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; RADIOSENSITIVITY; RECTUM CANCER; REVIEW; SOLID TUMOR; ULCER; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS;

EID: 67349256424     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.09.016     Document Type: Review

References (69)

1. Vokes E.E., Brizel D.M., and Lawrence T.S. Concomitant chemoradiotherapy. J Clin Oncol 25 (2007) 4031-4032
2. Deutsch E., Soria J.C., and Armand J.P. New concepts for phase I trials: evaluating new drugs combined with radiation therapy. Nat Clin Pract Oncol 2 (2005) 456-465
3. Seiwert T.Y., Salama J.K., and Vokes E.E. The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 4 (2007) 86-100
4. Buentzel J., Micke O., Adamietz I.A., Monnier A., Glatzel M., and de Vries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64 (2006) 684-691
5. Steel G.G., and Peckham M.J. Exploitable mechanisms in combined radiotherapy chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5 (1979) 85-91
6. Yang L.X., Douple E.B., O'Hara J.A., and Wang H.J. Production of DNA double-strand breaks by interactions between carboplatin and radiation: a potential mechanism for radiopotentiation. Radiat Res 143 (1995) 309-315
7. Wilson G.D., Bentzen S.M., and Harari P.M. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 16 (2006) 2-9
8. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
9. Kim J.J., and Tannock I.F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5 (2005) 516-525
10. Spring P.M., Arnold S.M., Shajahan S., et al. Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck. Cell Cycle 3 (2004) 479-485
11. Kidani Y., Noji M., and Tashiro T. Antitumor activity of platinum (II) complexes of 1,2-diamino-cyclohexane isomers. Gann 71 (1980) 637-643
12. Kovacs C.J., Schenken L.L., and Burholt D.R. Therapeutic potentiation of combined cis-dichlorodiammineplatinum (11) and irradiation by ICRF-159. Int J Radiat Oncol Biol Phys 5 (1979) 1361-1364
13. Freyer G., Bosard N., Romestaing P., et al. Addition of oxaliplatin to continous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol 19 (2001) 2433-2438
14. Blackstock A., Tepper J., and Hess S. Oxaliplatin: in vitro and in vivo evidence of its radiation sensitizing activity. Int J Rad Oncol Biol Phys 46 (2000) 92-94
15. Magné N., Fischel J.L., Formento P., et al. Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status. Oncology 64 (2003) 280-287
16. ® (gemcitabine) with thoracic radiotherapy-a phase II pilot study in chemonaive patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17 (1998) 499a
17. Lawrence T.S., Eisbruch A., McGinn, et al. Radiosensitization by gemcitabine. Oncology 13 (1999) 55-60
18. Blackstock A.W., Lesser G.J., Fletcher-Steede J., et al. Phase I study twice-weekly gemcitabine and concurrent thoracic radiotherapy for patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 51 (2001) 1281-1289
19. Vokes E.E., Herndon II J.E., Crawford J., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIb non-small-cell lung cancer: cancer and leukaemia group B study 9431. J Clin Oncol 20 (2002) 4191-4198
20. Van Putten J.W., Price A., van der Leest A.H., et al. A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 9 (2003) 2472-2477
21. Pignon J.P., Bourhis J., Domenge C., and Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355 (2000) 949-955
22. Seiwert T.Y., Salama J.K., and Vokes E.E. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 4 (2007) 156-171
23. Park J.K., Ryu J.K., Lee J.K., et al. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. Pancreas 33 (2006) 397-402
24. Huguet F., André T., Hammel P., et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25 (2007) 326-331
25. Hermisson M., Klumpp A., Wick W., et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96 (2006) 766-776
26. Wick W., Wick A., Schulz J.B., Dichgans J., Rodemann H.P., and Weller M. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 62 (2002) 1915-1919
27. Brock C.S., Newlands E.S., Wedge S.R., et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58 (1998) 4363-4367
28. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
29. Okawara G., Mackay J.A., Evans W.K., et al. Management of unresected stage III non-small cell lung cancer: a systematic review. J Thorac Oncol 1 (2006) 377-393
30. Kleinberg L., Gibson M.K., and Forastiere A.A. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nat Clin Pract Oncol 4 (2007) 282-294
31. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 1985; 312:1465-72.
32. Smalley S.R., Benedetti J.K., Williamson S.K., et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. Clin Oncol 24 (2006) 3542-3547
33. Chari R.S., Tyler D.S., Anscher M.S., et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 221 (1995) 778-787
34. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25 (2007) 4066-4074
35. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 (1997) 285-289
36. Dunst J. Management of anemia in patients undergoing curative radiotherapy. Erythropoietin, transfusions, or better nothing?. Strahlenther Onkol 180 (2004) 671-681
37. Henke M., Laszig R., Rube C., et al. Erythropietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
38. Machtay M., Pajak T.F., Suntharalingam M., et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the radiation therapy oncology group (RTOG 99-03). Int J Radiat Oncol Biol Phys 69 (2007) 1008-1017
39. Henke M., Mattern D., Pepe M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 24 (2006) 4708-4713
40. Rischin D., Hicks R.J., Fisher R., et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of trans-tasman radiation oncology group study 98.02. J Clin Oncol 24 (2006) 2098-2104
41. Dunst J. Erythropoietin and radiotherapy: a dangerous combination?. Strahlenther Onkol 180 (2004) 133-135
42. Sawada N., Ishikawa T., Sekiguchi F., Tanaka Y., and Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5 (1999) 2948-2953
43. Dupuis O., Vie B., Lledo G., et al. Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR Phase II Study. Oncology 73 (2007) 169-176
44. Hospers G.A., Punt C.J., Tesselaar M.E., et al. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. Ann Surg Oncol 14 (2007) 2773-2779
45. Small Jr. W., Berlin J., Freedman G.M., et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol 26 (2008) 942-947
46. Seiwert T.Y., Connell P.P., Mauer A.M., et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 13 (2007) 515-522
47. Cmelak A.J., Li S., Goldwasser M.A., et al. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 25 (2007) 3971-3977
48. Biagioli M.C., Harvey M., Roman E., et al. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 69 (2007) 1067-1073
49. Guerrero Urbano T., Clark C.H., Hansen V.N., et al. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol 85 (2007) 36-41
50. Ballonoff A., Kavanagh B., McCarter M., et al. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol 31 (2008) 264-270
51. Crane C.H., Antolak J.A., Rosen I.I., et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 30 (2001) 123-132
52. Xu X.G., Bednarz B., and Paganetti H. A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. Phys Med Biol 53 (2008) 193-241
53. Mendenhall W.M., Amdur R.J., and Palta J.R. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 24 (2006) 2618-2623
54. Magné N., Fischel J.L., Dubreuil A., et al. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86 (2002) 819-827
55. Harari P.M., Allen G.W., and Bonner J.A. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 25 (2007) 4057-4065
56. O'Reilly M.S. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 16 (2006) 45-50
57. Duda D.G., Jain R.K., and Willet C.G. Antiangiogenics: the potential role of intergrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25 (2007) 4033-4042
58. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
59. Cohen E.E., Kane M.A., List M.A., et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11 (2005) 8418-8424
60. Budach W., Bölke E., and Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 357 (2007) 514-515
61. Baumann M., Krause M., Dikomey E., et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 83 (2007) 238-248
62. Magné N., Chargari C., Castadot P., et al. The efficacy and toxicity of EGFR in the settings of radiotherapy: focus on published clinical trials. Eur J Cancer 44 (2008) 2133-2143
63. Crane C.H., Ellis L.M., Abbruzzese J.L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24 (2006) 1145-1151
64. Willet C.G., Boucher Y., Duda D.G., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23 (2005) 8136-8139
65. Czito B.G., Bendell J.C., Willet C.G., et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys 68 (2007) 472-478
66. Bruno R., Washington C.B., Lu J.F., Lieberman G., Banken L., and Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56 (2005) 361-369
67. Belkacémi Y., Gligorov J., Ozsahin M., et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol 19 (2008) 1110-1116
68. Koukourakis M.I., Manavis J., Simopoulos C., Liberis V., Giatromanolaki A., and Sivridis E. Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer. Am J Clin Oncol 28 (2005) 495-500
69. Schmidberger H., Hermann R.M., Hess C.F., et al. Interactions between radiation and endocrine therapy in breast cancer. Endocr Relat Cancer 10 (2003) 375-388